IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stephen R. WEDGE

Confirmation No: 1868

Serial No:

10/594,235

Group:

To be assigned

Filed:

September 22, 2006

Examiner:

To be assigned

Entitled:

COMBINATION THERAPY

ATTY DOCKET: 056291-5302

June 15, 2007

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENT

U.S. Patent and Trademark Office Randolph Building 401 Dulany Street Alexandria, Virginia 22314 MAIL STOP – PCT

Sir:

In response to the Communication from the Examiner dated June 7, 2007, Applicants hereby state that no sequence listing is required in this application, nor was a sequence listing filed in the parent PCT international application. The application does not disclose amino acid or nucleotide sequences. Thus, 37 CFR 1.821(c) does not apply.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R § 1.16 and § 1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bøckius LLP

Date:

June 15, 2007

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

			м и и.шрю.доч	
U.S. APPLICATION NUMBER NO.		FIRST NAMED APPLICANT	ATTY. DOCKET NO.	
10/594,235		Stephen Robert Wedge	056291-5302	
•			INTERNATIONAL AP	PLICATION NO.
			PCT/GB05	/01079
9629			I.A. FILING DATE	PRIORITY DATE
MORGAN LEWIS & BOCKIUS LLP			03/22/2005	03/23/2004
1111 PENNSYLVANIA WASHINGTON, DC 20 RECEIVED	Due Date A	1107 Attorney DJB 91-5302 7,2007 2007	CONFIRMATION NO. 1868 371 FORMALITIES LETTER	
GANTEMENER CRAMPS/FP	By PSF	chk	*OC000000024257814*	·

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR, 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197/or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

		· · · -
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/594.235	PCT/GB05/01079	056291-5302

FORM PCT/DO/EO/922 (371 Formalities Notice)

¿ . . •